Home
Home

Vernakalant

Cardiome to pay $20 million, settle debt deal with Merck

Cardiome to pay $20 million, settle debt deal with Merck
Reuters

Merck Returns To Cardiome All Rights To Atrial Fibrillation Drug Vernakalant

Merck Returns To Cardiome All Rights To Atrial Fibrillation Drug Vernakalant
Forbes

Cardiome Investors: Why Shares Crashed 50%

Cardiome Investors: Why Shares Crashed 50%
Motley Fool

Cardiome provides update on Merck's development plans for Vernakalant Oral

Cardiome provides update on Merck's development plans for Vernakalant Oral
The Fly on the Wall

Merck snags Astellas' U.S. rights to IV vernakalant

Merck snags Astellas' U.S. rights to IV vernakalant
Fierce Biotech

News

Cardiome shares battered by clinical trial halt
Marketwatch
»

News

Cardiome Jumps on Drug Progress
TheStreet.com
»

News

Merck says European Union agrees to review intravenous version of heart drug vernakalant
Yahoo/AP
»

News

Cardiome Pharma receives $15 million payment as part of Merck partnership
Yahoo/AP
»

News

Merck Strong in Cardiovasculars
Yahoo/Zacks.com
»